About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 414 record(s)
Req # A-2022-000059
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_05025498, E2B_04997253, 000982344. ADRs for Pantoprazole sodium. Report numbers: E2B_04987689, E2B_05023248, E2B_05042650, E2B_05078451, E2B_05002477, E2B_04988447, E2B_05059051.Organization: Health Canada
October 2022
Req # A-2022-000097
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB. Report numbers: E2B_05036607, E2B_05042570.Organization: Health Canada
October 2022
Req # A-2022-000124
Adverse Drug Reactions (ADRs). Report numbers: E2B_05046689, E2B_05047199 , E2B_05040991, E2B_05045866, E2B_05046386, E2B_05032965, E2B_05027426, E2B_05045924, E2B_05047237 E2B_05047153.Organization: Health Canada
October 2022
Req # A-2022-000135
Adverse Drug Reactions (ADRs). Report numbers: E2B_05023126, E2B_05041323, E2B_05020394, E2B_05027401, E2B_05046752, E2B_05047020, E2B_05041464, E2B_05046181, E2B_05041412, E2B_05046433.Organization: Health Canada
October 2022
Req # A-2022-000225
Adverse Drug Reactions (ADRs). Report numbers: E2B_04968642, E2B_04943076, E2B_04954829, E2B_04954821, E2B_04960737, E2B_04972409, E2B_04972379, E2B_04972477, 978332, E2B_04983059.Organization: Health Canada
October 2022
Req # A-2022-000239
Adverse Drug Reaction (ADR) for DOCUSATE SODIUM. Report number: 000973791.Organization: Health Canada
October 2022
Req # A-2022-000358
Adverse Drug Reactions (ADRs). Report numbers: 000988596, 000988428, 000987995, E2B_05235142.Organization: Health Canada
October 2022
Req # A-2022-000375
Adverse Drug Reactions (ADRs). Report numbers: E2B_05041575, E2B_05045986, E2B_05045988, E2B_05046442, E2B_05046446, E2B_05032838, E2B_05032949, E2B_05040687, E2B_05040721, E2B_05040754.Organization: Health Canada
October 2022
Req # A-2022-000440
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-104401-490, Deputy Heads Weekly Meeting.Organization: Health Canada
October 2022
Req # A-2022-000446
Adverse Drug Reaction (ADR) for Abilify Maintena. Report number: 000990033. ADRs for Aripiprazole. Report numbers: E2B_05217270, E2B_05239579. ADRs for Aripiprazole, Rexulti. Report numbers: E2B_05226096, E2B_05237961. ADRs for Patiromer. Report numbers: E2B_05283076, E2B_05298575, E2B_05307033.Organization: Health Canada
October 2022